RGD Reference Report - Therapeutic effects of signal transducer and activator of transcription 3 siRNA on human breast cancer in xenograft mice. - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

Therapeutic effects of signal transducer and activator of transcription 3 siRNA on human breast cancer in xenograft mice.

Authors: Yang, Z  Cai, JH  Xie, SJ  Li, GX  Song, WQ  Yan, QH  Yan, L  Zhang, F 
Citation: Yang Z, etal., Chin Med J (Engl). 2011 Jun;124(12):1854-61.
RGD ID: 8694286
Pubmed: PMID:21740845   (View Abstract at PubMed)

BACKGROUND: Signal transducer and activator of transcription 3 (STAT3) is usually constitutively activated in a variety of malignancies. It directly contributes to tumorigenesis, invasion, and metastasis. The surgical treatment of breast cancer has made no breakthroughs in terms of treatment effect, in spite of its long history. Current biotherapies bring a note of optimism to breast cancer treatment. To explore the possibility of a siRNA targeted STAT3 blocking treatment for over-activated tumor cells, we evaluated the efficacy of a STAT3 siRNA on human breast cancer cells in vitro and in vivo. METHODS: Three MCF-7 human breast cancer cell lines were tested: control MCF-7 cells, non-specific siRNA transfected MCF-7 cells and STAT3 siRNA transfected MCF-7 cells. Expression of STAT3 in MCF-7 cells was inhibited by RNA interference (RNAi). The STAT3 mRNA and protein levels were detected by semi-quantity RT-PCR and Western blotting. Cell proliferation and apoptosis were determined by MTT method and flow cytometry. The three groups of MCF-7 cells mentioned above were transplanted subcutanuously into nude mice and their tumorgenic ability observed. The STAT3 mRNA and protein levels of the samples from tumors in different groups were determined by semi-quantity RT-PCR and Western blotting and compared. RESULTS: In STAT3 siRNA transfected MCF-7 cells, the expressions (STAT3/beta-actin) of STAT3 mRNA (0.327 +/- 0.020) and protein (0.153 +/- 0.006) were significantly lower than that in control MCF-7 cells (mRNA 1.093 +/- 0.018, protein 1.374 +/- 0.022) and non-specific siRNA transfected MCF-7 cells (mRNA 1.035 +/- 0.050, protein 1.320 +/- 0.033) (P < 0.05). MTT showed that cell proliferation was significantly reduced and the cell growth inhibition ratio in the STAT3-siRNA group was (44.00 +/- 5.10)%, significantly higher than that in non-specific siRNA transfected MCF-7 cells ((16.10 +/- 1.05)%, P < 0.05). Flow cytometry results showed that more apoptosis was observed in the STAT3-siRNA group. The rate of apoptosis was (14.79 +/- 0.22)%, much higher than in control MCF-7 cells (7.06 +/- 0.71) and non-specific siRNA transfected MCF-7 cells (8.45 +/- 0.43) (P < 0.05). The tumor growth in the STAT3 siRNA transfected MCF-7 cells was significantly slower than in the two control groups. On the 22th day after transplantation the tumor weight ((21.40 +/- 10.57) mg) and volume ((41.15 +/- 12.17) mm(3)) in the STAT3 siRNA transfected group were significantly lower than in control group (weight (88.60 +/- 12.16) mg, volume (118.45 +/- 24.68) mm(3)) and non-specific siRNA transfected group (weight (57.20 +/- 21.86) mg, volume (101.36 +/- 21.90) mm(3)) (P < 0.05). Both the STAT3 mRNA and protein levels in the tumors from the STAT3 siRNA transfected group were significantly lower than in the tumors from the two control groups. CONCLUSIONS: STAT3 siRNA can effectively silence the STAT3 gene in vitro and in vivo, increase cell apoptosis rate and significantly decrease cell proliferation, which inhibits the growth of breast cancer cell in vitro. Tumor growth of xenograft mice is significantly inhibited. The results obtained in vivo are in consistency with those in vitro. STAT3 may be a novel therapeutic target for breast cancer and RNA interference has potential clinical application.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
STAT3Humanbreast cancer treatmentIMP  RGD 
Stat3Ratbreast cancer treatmentISOSTAT3 (Homo sapiens) RGD 
Stat3Mousebreast cancer treatmentISOSTAT3 (Homo sapiens) RGD 

Objects Annotated

Genes (Rattus norvegicus)
Stat3  (signal transducer and activator of transcription 3)

Genes (Mus musculus)
Stat3  (signal transducer and activator of transcription 3)

Genes (Homo sapiens)
STAT3  (signal transducer and activator of transcription 3)


Additional Information